Simple blood test to detect Alzheimerās disease gets US regulator’s nod
HQ Team May 18, 2025: The US Food and Drug Administration has granted marketing access to Fujirebio Diagnostics, Inc.ās blood test to diagnose.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team May 18, 2025: The US Food and Drug Administration has granted marketing access to Fujirebio Diagnostics, Inc.ās blood test to diagnose.
HQ Team May 16, 2025: The world is losing its battle against hunger. The latestĀ Global Report on Food CrisesĀ reveals a sixth consecutive year.
HQ Team May 16, 2025: Dengue fever has become a serious and growing health threat in India, especially between July and mid-November. Recent.
HQ Team May 14, 2025: The US regulator is initiating action to remove concentrated ingestible fluoride prescription drug products for children from the.
HQ Team May 15, 2025: A recent meta research by DrĀ Salvatore CortellinoĀ and ProfessorĀ Antonio Giordano, President of theĀ Sbarro Health Research OrganizationĀ (SHRO) and molecular oncologist.
Ā HQ Team May 15, 2025: The US Food and Drug Administration (FDA) has granted an accelerated approval for AbbVie Inc.ās drug to treat.
HQ Team May 15, 2025: Harvard University has amended its lawsuit against the US administration by saying that its researchers would lose another.
HQ Team May 15, 2025: Merck & Co. got approval from the US Food and Drug Administration for a pill to treat a.
HQ Team May 14, 2025: Novo Nordisk and Septerna, Inc., have inked a $2.2 billion global collaboration and licensing pact to develop oral.
HQ Team May 14, 2025: GSK Plc will acquire Boston Pharmaceuticalās investigational lead asset, efimosfermin alfa, to treat serious liver diseases, for $2.